Switch to:
» Details

Insider Trades

Latest Guru Trades with MYOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:CYIG, OTCPK:TRLPF, OTCPK:IMLFF, OTCPK:BKIT, OTCPK:CBICF, OTCPK:EMMBF, OTCPK:PARNF, OTCPK:RLMD, NAS:PTX, NAS:APRI, OTCPK:GLDFF, OTCPK:AQSZF, NAS:SNOA, OTCPK:CVSI, NAS:BNTC, NAS:ACUR, OTCPK:PUFXF, NAS:ARDM, OTCPK:AOLS, AMEX:IGC » details
MYOS Corp is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue.

MYOS Corp was incorporated in the State of Nevada on April 11, 2007. The Company is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue. In February 2011, the Company acquired its platform dietary supplement product called MYO-T12. Its trademark includes FORTETROPIN. Its competition includes numerous nutritional supplement companies that are fragmented in terms of geographic market coverage, distribution channels and product categories.

Ratios

vs
industry
vs
history
P/B 2.77
MYOS's P/B is ranked lower than
55% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. MYOS: 2.77 )
Ranked among companies with meaningful P/B only.
MYOS' s P/B Range Over the Past 10 Years
Min: 0.93  Med: 3.39 Max: 16.26
Current: 2.77
0.93
16.26
P/S 35.80
MYOS's P/S is ranked lower than
92% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. MYOS: 35.80 )
Ranked among companies with meaningful P/S only.
MYOS' s P/S Range Over the Past 10 Years
Min: 4.15  Med: 19 Max: 465.12
Current: 35.8
4.15
465.12
Current Ratio 4.06
MYOS's Current Ratio is ranked higher than
70% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. MYOS: 4.06 )
Ranked among companies with meaningful Current Ratio only.
MYOS' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 4.06 Max: 27.24
Current: 4.06
0.03
27.24
Quick Ratio 2.49
MYOS's Quick Ratio is ranked higher than
62% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. MYOS: 2.49 )
Ranked among companies with meaningful Quick Ratio only.
MYOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 2.76 Max: 26.31
Current: 2.49
0.03
26.31
Days Inventory 900.52
MYOS's Days Inventory is ranked lower than
100% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. MYOS: 900.52 )
Ranked among companies with meaningful Days Inventory only.
MYOS' s Days Inventory Range Over the Past 10 Years
Min: 43.32  Med: 251.52 Max: 1919.9
Current: 900.52
43.32
1919.9
Days Sales Outstanding 1.09
MYOS's Days Sales Outstanding is ranked higher than
98% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. MYOS: 1.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.09  Med: 80.84 Max: 932.01
Current: 1.09
1.09
932.01
Days Payable 142.01
MYOS's Days Payable is ranked higher than
82% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. MYOS: 142.01 )
Ranked among companies with meaningful Days Payable only.
MYOS' s Days Payable Range Over the Past 10 Years
Min: 20.31  Med: 44.16 Max: 153.49
Current: 142.01
20.31
153.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.30
MYOS's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. MYOS: -17.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.3  Med: -24.1 Max: -8.4
Current: -17.3
-32.3
-8.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.35
MYOS's Price/Net Cash is ranked lower than
51% of the 250 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.84 vs. MYOS: 9.35 )
Ranked among companies with meaningful Price/Net Cash only.
MYOS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.28  Med: 6.81 Max: 34.02
Current: 9.35
2.28
34.02
Price/Net Current Asset Value 4.20
MYOS's Price/Net Current Asset Value is ranked higher than
65% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MYOS: 4.20 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MYOS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.55  Med: 5.56 Max: 80.17
Current: 4.2
1.55
80.17
Price/Tangible Book 3.92
MYOS's Price/Tangible Book is ranked lower than
61% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. MYOS: 3.92 )
Ranked among companies with meaningful Price/Tangible Book only.
MYOS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.48  Med: 5.22 Max: 81.01
Current: 3.92
1.48
81.01
Price/Median PS Value 1.88
MYOS's Price/Median PS Value is ranked lower than
86% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. MYOS: 1.88 )
Ranked among companies with meaningful Price/Median PS Value only.
MYOS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1.06 Max: 19.51
Current: 1.88
0.26
19.51
Earnings Yield (Greenblatt) (%) -36.89
MYOS's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. MYOS: -36.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYOS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -154.84  Med: 181.1 Max: 74436.8
Current: -36.89
-154.84
74436.8

More Statistics

Revenue (TTM) (Mil) $0.34
EPS (TTM) $ -1.17
Beta1.68
Short Percentage of Float7.62%
52-Week Range $1.02 - 6.98
Shares Outstanding (Mil)5.34
» More Articles for MYOS

Headlines

Articles On GuruFocus.com

More From Other Websites
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Feb 21 2017
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... Feb 14 2017
MYOS RENS Technology Inc. Adopts Shareholder Rights Plan Feb 14 2017
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation... Feb 07 2017
Key Catalyst That Could Send Biotechs Soaring in 2017: Today's Reports on MYOS RENS Technology and... Feb 06 2017
MYOS RENS Technology Inc. Announces $2,125,000 Registered Direct Offering Feb 03 2017
Dr. Robert Hariri, stem cell pioneer and chairman of MYOS RENS Technology, states that 'healthy... Jan 30 2017
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 23 2017
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jan 11 2017
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 22 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 25 2016
MYOS RENS TECHNOLOGY INC. Financials Nov 22 2016
MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 Nov 18 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 10-Q, Quarterly Report Nov 14 2016
MYOS RENS Announces Publication of Its Fortetropin(R) Human Clinical Trial Manuscript Sep 29 2016
MYOS RENS Announces Publication of Its Fortetropin(R) Human Clinical Trial Manuscript Sep 29 2016
MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer Sep 07 2016
MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer Sep 07 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers Aug 31 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Aug 24 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK